Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

Novartis drug combo shows promise in childhood brain cancer

An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

Reuters

Work on environmental and economic Novartis 'leaving gift' legacy begins

Wetland habitat to be created to enable future inward investment and economic development at pace

Birmingham Post

KTR hardsells Telangana at Davos

Meets top honchos of tech and pharma companies

The Hindu

From analysis to the latest developments in health,
read the most diverse news in one place.

Buyer of Novartis Grimsby outlines what could be next for 'world-class' pharmaceutical complex

International Process Plants has taken it on under new subsidiary Humber Industrials Ltd - eyeing onshoring of production as a possibility

Birmingham Post

Cancer Coalition Aims to Boost Access to Medicines in Poorer Countries

Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries. Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries,…

Asharq Al-Awsat

All Novartis jobs to go as land and process plant sale agreed with international industrial dealer

Slim hopes of a going concern sale of Grimsby site appear to have been dashed - with remaining 212 employees now facing redundancy

Birmingham Post

5 Value Stocks In The Healthcare Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

5 Value Stocks To Watch In The Healthcare Sector

What Defines a Value Stock?

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

Upgrades

Benzinga

‘Please pay attention’: Scientist flagged heart-pill toxins early on

A scientist at a China-based company that makes crucial ingredients for generic drugs warned a year before the start of a global recall that some blood-pressure pills could become tainted with potentially cancer-causing chemicals, according to court documents.

Tribune News Service

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Why Molecular Partners Shares Are Getting Hammered

Molecular Partners AG (NASDAQ: MOLN) shares are trading lower by 36.52% at $8.38 after the company and its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.

Benzinga

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

Benzinga

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

Molecular Partners AG (NASDAQ:MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be authorized. Vas Narasimhan also noted that the current omicron wave of SARS-Cov-2,…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novartis: Q1 Earnings Insights

Novartis (NYSE:NVS) reported its Q1 earnings results on Tuesday, April 26, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook

Novartis AG (NYSE:NVS) has reported a core EPS of $1.46 in Q1 FY22 compared to $1.38 a year ago, beating the consensus of $1.44. Net income reached $2.2 billion, an increase of 8% or 15% at constant currency rates, mainly driven by higher operating income, partly offset by the loss of Roche Holding (OTC:RHHBY) income.…

Benzinga

Novartis Earnings Preview

Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Novartis will report an earnings per share (EPS) of $1.44.

The Guardian - UK

Medical regulator faces questions over board members’ links to drug firms

Concerns over potential conflicts of interest lead to calls for regulator’s policy to be strengthened

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Golden Cross Appears Before Novartis Investors

If history is any guide, there may be good fortune ahead for shares of Novartis (NYSE:NVS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

Hopeful Golden Cross Forms On Novartis's Chart

Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Overview Of Value Stocks In The Healthcare Sector

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga

Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication

The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Benzinga

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis

Novartis AG (NYSE:NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis. The data demonstrated long-term efficacy and safety of Kesimpta with continued reduced risk of disability worsening in relapsing multiple sclerosis following up to four years of treatment. Kesimpta…

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.